Mornings in the Lab with Keith, Jon & Friends LIVE
Over 40 and Losing Strength? Liz Parrish, Gene Therapy's Patient Zero
Published · 33 min
About this episode
At 44, she secretly flew to Colombia and became the first person in history to undergo gene therapy to reverse aging. Her husband found out eight months later — in a Wired magazine article. Liz Parrish is the CEO of Bioviva Sciences and "Patient Zero" for telomere-lengthening gene therapy. In this interview, she breaks down exactly what she did, how her telomeres lengthened by 20 years within months, and why she believes aging itself is a treatable disease. Jon Andersen joins the conversation to compare his experience with peptide therapy and epitalon. Topics covered: - How gene therapy lengthens telomeres and what that means for lifespan - Liz’s results: chronologically 54, biologically in her 20s-30s - Stem cells vs. exosomes vs. gene therapy — which actually works - Why gene therapy costs $2-7 million in the US and how Bioviva is changing that - The "playing God" debate and why she calls it medicine catching up - Her son’s Type 1 diabetes: the personal story behind the mission - Big pharma’s subscription model vs. a one-time gene therapy fix - What the longevity influencer industry gets wrong Guest: Liz Parrish — CEO & Founder, Bioviva Sciences | bioviva-science.com #genetherapy #reverseaging #telomeres #lizparrish #bioviva #longevity #antiaging #biohacking #stemcells #morningsinthelab #keithbilous #jonandersen #menshealth #wellness kB
People in this conversation
Read the guest conversations
Explore the available interview transcripts on each guest’s profile.